Developer docs
API playgroundTry for free, no card

Search company profiles

Parnell Living Science

Full company profile

uuid0005qzu

Namestring
Parnell Living Science
Legal namestring
Parnell Technologies Pty. Ltd.
Company typeenum
Private
Founded yearint
1968
Descriptiontext

Parnell Living Science is a fully integrated veterinary pharmaceutical company operating across livestock and companion-animal segments in approximately 14 countries, with its U.S. headquarters in Overland Park, Kansas and regional offices in Australia and New Zealand. The company develops, manufactures, and markets FDA- and EMA-accredited sterile veterinary pharmaceuticals including reproductive hormones (GONAbreed, estroPLAN), bovine respiratory disease treatments (RESPIRmycin, nixiFLOR), and a companion-animal anesthesia, sedation, and euthanasia portfolio (PropofolVet Multidose, Dexmedetomidine, CONTRASED, Isoflurane, Pentobarbital Sodium/Phenytoin). In November 2025 it acquired Noble Pharma LLC, adding FDA- and DEA-accredited U.S. manufacturing capacity and enabling contract manufacturing services.

The company's go-to-market is a hybrid sales-led motion combining direct engagement with herd-health veterinarians and livestock producers with a deep distributor network — 13 livestock partners (MWI, Animal Health International, Leedstone, Vedco, etc.) and 5 pet care partners (Covetrus, Patterson Veterinary, Amatheon, First Veterinary Supply, Penn Veterinary Supply). Revenue is generated primarily through one-time pharmaceutical product sales, supplemented by subscription/recurring digital services through the mySYNCH cloud-based herd management platform (which tracks 1M+ milking cows and 2.2M+ animals), a $299/user RACE-approved CE certificate program gated to qualifying product purchases, and new contract manufacturing revenue from the Wisconsin facility.

Parnell's stated strategy is a 'Beyond the Bottle' model bundling pharmaceuticals with the mySYNCH digital platform, on-farm technical services, compliance training, and reproductive reviews. The company has prioritized first-mover FDA generic approvals (nixiFLOR, PropofolVet Multidose) and has executed an active 2025–2026 expansion through acquisition, product launches, and new financing. Reported as publicly traded on otcpink:PARNF with leadership including CEO Wes Dittmer and CFO/COO Brad McCarthy, though the provided financial disclosures contain apparent unit errors and require independent verification.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersOverland Park, United States
HQ citystring
Overland Park
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
veterinary pharmaceuticals, animal health products, livestock reproductive solutions, companion animal anesthesia, herd management software
Industry4 codes
1Veterinary Pharmacy, Vaccine & Biologics Services
CodeAFAEANAKPrimaryYes
2Pain Management, Anesthesia & Critical Care Drugs
CodeHLAMAEAFPrimaryNo
3Livestock & Farm Animal Veterinary Services
CodeAFAEANABPrimaryNo
4Food Animal (Bovine/Dairy/Beef) Veterinary Services
CodeHLAMABAAPrimaryNo
NAICS code2 codes
  • Veterinary Services541940
  • Support Activities for Animal Production1152
SIC code2 codes
  • Agricultural Prod-Livestock & Animal Specialties200
  • Wholesale-Medical, Dental & Hospital Equipment & Supplies5047
Product category
Veterinary Pharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Parnell generates revenue through the sale of veterinary pharmaceutical products including livestock products (GONAbreed, estroPLAN, RESPIRmycin, nixiFLOR) and pet care products (PropofolVet Multidose, Dexmedetomidine, CONTRASED, Isoflurane, Pentobarbital Sodium/Phenytoin). Products are sold through distributors and directly to veterinarians.

parnell.com
2Education and Certificate Programs
TypeOne Time License
Description

Revenue generated through the Foundations of Anesthesia & Sedation Veterinary Certificate program, valued at $299/user, offered exclusively to clinics purchasing qualifying Parnell manufactured products. This creates a demand generation mechanism while generating direct revenue.

parnell.com
3Contract Manufacturing Services
TypeProfessional Services
Description

Following the acquisition of Noble Pharma LLC, Parnell offers contract manufacturing capabilities from its FDA- and DEA-accredited facility in Menomonie, Wisconsin. The facility specializes in various pharmaceutical forms including suspensions, liquids, tablets, boluses, powders, gels, pastes, creams, and ointments.

pulse2.com
4Digital Technology Services (mySYNCH)
TypeSubscription Recurring
Description

The mySYNCH platform and services generate revenue through a combination of software access, data analytics services, on-farm support, compliance training, and reproductive reviews for dairy operations.

parnell.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Foundations of Anesthesia & Sedation Certificate - $299/user single license
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Single license valued at $299/user. Exclusive program for clinics purchasing qualifying Parnell manufactured products. Clinics earn 2 users for every $500 spent on qualifying products (purchase at least $500 to qualify, then tiered: $500=2 users, $1000=4 users, $1500=6 users, $2000=8 users, $2500=10 users).

parnell.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 10 records shown
1mySYNCH
Description

Comprehensive suite of digital technology, services, and insights for dairy herd reproductive management, combining advanced analytics, on-farm support, and compliance training.

parnell.com
+9 more records
Core offering1 text field

Parnell is a fully integrated veterinary pharmaceutical company that develops, manufactures, and markets FDA- and EMA-approved animal health products for livestock (dairy and beef reproduction and respiratory health) and companion animals (anesthesia, sedation, pain management, euthanasia). The company complements its drug portfolio with the mySYNCH digital herd-management platform, contract manufacturing services, and veterinary continuing-education programs, distributing through major animal-health distributors and herd-health veterinarians in 14 countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • nixiFLOR provides visible improvement in as little as 6 hours for BRD treatment
+2 more records
Product and service12 records
1GONAbreed
CategoryLivestock reproductive pharmaceuticals
Description

Gonadorelin acetate veterinary product for treatment of cystic ovaries and use in cattle synchronization protocols to optimize timed artificial insemination. Used by dairy and beef producers and their veterinarians.

2estroPLAN
CategoryLivestock reproductive pharmaceuticals
Description

Cloprostenol sodium prostaglandin solution used to induce regression of the corpus luteum and manipulate the estrous cycle in cattle. Used by herd-health veterinarians managing dairy and beef reproductive programs.

3RESPIRmycin
CategoryLivestock respiratory pharmaceuticals
Description

Tulathromycin injection indicated for treatment of bovine and swine respiratory disease, used in beef cattle, dairy cattle, calves, and swine. Sold to livestock producers and veterinarians.

4nixiFLOR
CategoryLivestock respiratory pharmaceuticals
Description

First FDA-approved generic florfenicol + flunixin meglumine combination administered as a single-dose subcutaneous injection for treatment of bovine respiratory disease (BRD) in beef and non-lactating dairy cattle. Targeted at livestock producers and herd-health veterinarians needing a cost-effective BRD therapy.

5PropofolVet Multidose
CategoryCompanion animal anesthesia pharmaceuticals
Description

First generic propofol injectable emulsion for dogs, used for induction and maintenance of general anesthesia. Sold to companion-animal veterinary practices.

6Dexmedetomidine Hydrochloride Injection
CategoryCompanion animal sedation pharmaceuticals
Description

Sedative and analgesic injection for dogs and cats used during clinical examinations, procedures, and preanesthesia. Sold to companion-animal veterinary practices.

7CONTRASED
CategoryCompanion animal anesthesia pharmaceuticals
Description

Atipamezole hydrochloride injection used for rapid reversal of dexmedetomidine effects in dogs. Sold to companion-animal veterinary practices to support sedation reversal protocols.

8Isoflurane Inhalation Anesthetic
CategoryCompanion animal anesthesia pharmaceuticals
Description

Inhalant anesthetic for induction and maintenance of general anesthesia in horses and dogs. Sold to veterinary practices for use in companion-animal and equine procedures.

9Pentobarbital Sodium and Phenytoin Sodium Euthanasia Solution
CategoryCompanion animal euthanasia pharmaceuticals
Description

Euthanasia solution for dogs delivering humane, painless, and rapid euthanasia, supplied in 100 mL multi-dose vials. Sold to companion-animal veterinary practices for end-of-life care.

10mySYNCH Platform and Services
CategoryDigital herd management software and services
Description

Cloud-based web application and service bundle that transforms herd-management data into insights for dairy reproductive management, combining advanced analytics, on-farm support, compliance training, and reproductive reviews. Tracks over 1 million milking cows and serves a community database of over 2.2 million animals. Used by dairy operations.

11Foundations of Anesthesia & Sedation Veterinary Certificate
CategoryVeterinary professional education
Description

RACE-approved continuing-education certificate program delivering 10 CE hours on anesthesia and sedation, created with veterinary professionals and exclusive to clinics purchasing qualifying Parnell-manufactured products. Priced at $299 per user, with tiered access based on product purchases. Sold to companion-animal veterinary clinics.

12Contract Manufacturing Services
CategoryPharmaceutical contract manufacturing
Description

FDA- and DEA-accredited contract manufacturing services delivered from the Menomonie, Wisconsin facility acquired through Noble Pharma LLC, covering suspensions, liquids, tablets, boluses, powders, gels, pastes, creams, and ointments. Offered to pharmaceutical companies seeking third-party manufacturing capacity.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-11-26
Description

Parnell acquired Noble Pharma LLC, a U.S.-based FDA- and DEA-accredited pharmaceutical manufacturer located in Menomonie, Wisconsin. The acquisition strengthens Parnell's U.S. manufacturing footprint with capabilities spanning suspensions, liquids, tablets, boluses, powders, gels, pastes, creams, and ointments. This positions Parnell for continued expansion across the U.S. market and enables increased production and innovation.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Parnell partnered with IGNITE, a veterinary learning company, to develop the Foundations of Anesthesia & Sedation Veterinary Certificate program. The program was created by veterinary professionals in anesthesia, critical care, neurology, and pharmacology and provides 10 RACE-approved CE hours exclusively to clinics purchasing qualifying Parnell manufactured products.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

World's largest pure-play animal health company; directly competes across livestock reproductive/respiratory pharmaceuticals and companion-animal anesthesia/sedation, making it Parnell's most direct large-cap peer.

TypeDirect peer
Description

Global animal health pharmaceutical company with overlapping livestock (reproductive, BRD) and companion-animal portfolios; competes head-to-head with Parnell's branded and generic product lines.

TypeDirect peer
Description

Animal health division of Merck offering vaccines, pharmaceuticals, and digital tools for livestock and pets; competes with Parnell's livestock reproductive/respiratory portfolio and pet anesthesia/sedation range.

TypeDirect peer
Description

Independent global animal health company with companion-animal focus including anesthesia/sedation; a close functional peer to Parnell's pet-care anesthesia portfolio (Dexmedetomidine, propofol, isoflurane).

TypeDirect peer
Description

Specialty veterinary pharma focused on companion-animal endocrinology, anesthesia, and critical care; directly comparable to Parnell's pet-care segment across sedation, euthanasia, and pain products.

TypeDirect peer
Description

Animal health and nutrition company with strong livestock pharmaceutical and medicated feed additive portfolio; comparable to Parnell's livestock product range targeting dairy and beef producers.

TypeDirect peer
Description

French veterinary pharma with companion-animal and livestock portfolios including reproductive and respiratory products; competes with Parnell in specialty vet pharmaceutical niches across multiple geographies.

TypeBroad incumbent
Description

Top-3 global animal health franchise offering vaccines, parasiticides, and pharmaceuticals across species; broader portfolio but comparable in livestock reproductive/respiratory therapeutics where Parnell competes.

TypeBroad incumbent
Description

Large privately-held animal health company spanning pharmaceuticals, vaccines, and digital monitoring for livestock and pets; competes with Parnell across species but at greater scale and with broader product breadth.

10Valley Ag Software (DairyComp / PULSE)
TypeEmerging player
Description

Dairy herd management software provider with longstanding on-farm installed base; directly competes with mySYNCH for dairy operation data analytics and reproductive program management.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Parnell Living Science

Veterinary Pharmaceuticalsparnell.com

What Parnell Living Science does

Parnell Living Science is a fully integrated veterinary pharmaceutical company operating across livestock and companion-animal segments in approximately 14 countries, with its U.S. headquarters in Overland Park, Kansas and regional offices in Australia and New Zealand. The company develops, manufactures, and markets FDA- and EMA-accredited sterile veterinary pharmaceuticals including reproductive hormones (GONAbreed, estroPLAN), bovine respiratory disease treatments (RESPIRmycin, nixiFLOR), and a companion-animal anesthesia, sedation, and euthanasia portfolio (PropofolVet Multidose, Dexmedetomidine, CONTRASED, Isoflurane, Pentobarbital Sodium/Phenytoin). In November 2025 it acquired Noble Pharma LLC, adding FDA- and DEA-accredited U.S. manufacturing capacity and enabling contract manufacturing services.

The company's go-to-market is a hybrid sales-led motion combining direct engagement with herd-health veterinarians and livestock producers with a deep distributor network — 13 livestock partners (MWI, Animal Health International, Leedstone, Vedco, etc.) and 5 pet care partners (Covetrus, Patterson Veterinary, Amatheon, First Veterinary Supply, Penn Veterinary Supply). Revenue is generated primarily through one-time pharmaceutical product sales, supplemented by subscription/recurring digital services through the mySYNCH cloud-based herd management platform (which tracks 1M+ milking cows and 2.2M+ animals), a $299/user RACE-approved CE certificate program gated to qualifying product purchases, and new contract manufacturing revenue from the Wisconsin facility.

Parnell's stated strategy is a 'Beyond the Bottle' model bundling pharmaceuticals with the mySYNCH digital platform, on-farm technical services, compliance training, and reproductive reviews. The company has prioritized first-mover FDA generic approvals (nixiFLOR, PropofolVet Multidose) and has executed an active 2025–2026 expansion through acquisition, product launches, and new financing. Reported as publicly traded on otcpink:PARNF with leadership including CEO Wes Dittmer and CFO/COO Brad McCarthy, though the provided financial disclosures contain apparent unit errors and require independent verification.

Parnell Living Science firmographics

Firmographics
Name
Parnell Living Science
Legal name
Parnell Technologies Pty. Ltd.
Website
http://www.parnell.com/
Company type
Private
Founded year
1968
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

Parnell Living Science industry classification

Industry
Product category
Veterinary Pharmaceuticals
NAICS
Veterinary Services (541940), Support Activities for Animal Production (1152)
SIC
Agricultural Prod-Livestock & Animal Specialties (200), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
akta.pro primary industry
Veterinary Pharmacy, Vaccine & Biologics Services (AFAEANAK)
akta.pro secondary industries
Pain Management, Anesthesia & Critical Care Drugs (HLAMAEAF), Livestock & Farm Animal Veterinary Services (AFAEANAB), Food Animal (Bovine/Dairy/Beef) Veterinary Services (HLAMABAA)

Keywords

  • Veterinary pharmaceuticals
  • Animal health products
  • Livestock reproductive solutions
  • Companion animal anesthesia
  • Herd management software

Where Parnell Living Science is headquartered

Location

Headquarters

HQ city
Overland Park
HQ country
United States
HQ region
North America

Offices5 records

Markets served

Parnell Living Science business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Product Sales: Parnell generates revenue through the sale of veterinary pharmaceutical products including livestock products (GONAbreed, estroPLAN, RESPIRmycin, nixiFLOR) and pet care products (PropofolVet Multidose, Dexmedetomidine, CONTRASED, Isoflurane, Pentobarbital Sodium/Phenytoin). Products are sold through distributors and directly to veterinarians.
  2. Education and Certificate Programs: Revenue generated through the Foundations of Anesthesia & Sedation Veterinary Certificate program, valued at $299/user, offered exclusively to clinics purchasing qualifying Parnell manufactured products. This creates a demand generation mechanism while generating direct revenue.
  3. Contract Manufacturing Services: Following the acquisition of Noble Pharma LLC, Parnell offers contract manufacturing capabilities from its FDA- and DEA-accredited facility in Menomonie, Wisconsin. The facility specializes in various pharmaceutical forms including suspensions, liquids, tablets, boluses, powders, gels, pastes, creams, and ointments.
  4. Digital Technology Services (mySYNCH): The mySYNCH platform and services generate revenue through a combination of software access, data analytics services, on-farm support, compliance training, and reproductive reviews for dairy operations.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goFoundations of Anesthesia & Sedation Certificate - $299/user single license

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Parnell Living Science product offering

Product offering

Core offering

Parnell is a fully integrated veterinary pharmaceutical company that develops, manufactures, and markets FDA- and EMA-approved animal health products for livestock (dairy and beef reproduction and respiratory health) and companion animals (anesthesia, sedation, pain management, euthanasia). The company complements its drug portfolio with the mySYNCH digital herd-management platform, contract manufacturing services, and veterinary continuing-education programs, distributing through major animal-health distributors and herd-health veterinarians in 14 countries.

Differentiator

Problem solved

Functional benefit

Brands

  • mySYNCH: Comprehensive suite of digital technology, services, and insights for dairy herd reproductive management, combining advanced analytics, on-farm support, and compliance training.
  • nixiFLOR
  • GONAbreed
  • estroPLAN
  • RESPIRmycin
  • PropofolVet Multidose
  • Dexmedetomidine Hydrochloride Injection
  • CONTRASED
  • Isoflurane Inhalation Anesthetic
  • Pentobarbital Sodium and Phenytoin Sodium Euthanasia Solution

Products and services

  • GONAbreed Gonadorelin acetate veterinary product for treatment of cystic ovaries and use in cattle synchronization protocols to optimize timed artificial insemination. Used by dairy and beef producers and their veterinarians.
  • estroPLAN Cloprostenol sodium prostaglandin solution used to induce regression of the corpus luteum and manipulate the estrous cycle in cattle. Used by herd-health veterinarians managing dairy and beef reproductive programs.
  • RESPIRmycin Tulathromycin injection indicated for treatment of bovine and swine respiratory disease, used in beef cattle, dairy cattle, calves, and swine. Sold to livestock producers and veterinarians.
  • nixiFLOR First FDA-approved generic florfenicol + flunixin meglumine combination administered as a single-dose subcutaneous injection for treatment of bovine respiratory disease (BRD) in beef and non-lactating dairy cattle. Targeted at livestock producers and herd-health veterinarians needing a cost-effective BRD therapy.
  • PropofolVet Multidose First generic propofol injectable emulsion for dogs, used for induction and maintenance of general anesthesia. Sold to companion-animal veterinary practices.
  • Dexmedetomidine Hydrochloride Injection Sedative and analgesic injection for dogs and cats used during clinical examinations, procedures, and preanesthesia. Sold to companion-animal veterinary practices.
  • CONTRASED Atipamezole hydrochloride injection used for rapid reversal of dexmedetomidine effects in dogs. Sold to companion-animal veterinary practices to support sedation reversal protocols.
  • Isoflurane Inhalation Anesthetic Inhalant anesthetic for induction and maintenance of general anesthesia in horses and dogs. Sold to veterinary practices for use in companion-animal and equine procedures.
  • Pentobarbital Sodium and Phenytoin Sodium Euthanasia Solution Euthanasia solution for dogs delivering humane, painless, and rapid euthanasia, supplied in 100 mL multi-dose vials. Sold to companion-animal veterinary practices for end-of-life care.
  • mySYNCH Platform and Services Cloud-based web application and service bundle that transforms herd-management data into insights for dairy reproductive management, combining advanced analytics, on-farm support, compliance training, and reproductive reviews. Tracks over 1 million milking cows and serves a community database of over 2.2 million animals. Used by dairy operations.
  • Foundations of Anesthesia & Sedation Veterinary Certificate RACE-approved continuing-education certificate program delivering 10 CE hours on anesthesia and sedation, created with veterinary professionals and exclusive to clinics purchasing qualifying Parnell-manufactured products. Priced at $299 per user, with tiered access based on product purchases. Sold to companion-animal veterinary clinics.
  • Contract Manufacturing Services FDA- and DEA-accredited contract manufacturing services delivered from the Menomonie, Wisconsin facility acquired through Noble Pharma LLC, covering suspensions, liquids, tablets, boluses, powders, gels, pastes, creams, and ointments. Offered to pharmaceutical companies seeking third-party manufacturing capacity.

Quantifiable outcome

  • nixiFLOR provides visible improvement in as little as 6 hours for BRD treatment
  • +2 more outcomes

Companies that use Parnell Living Science

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Parnell Living Science technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Parnell Living Science partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Noble Pharma LLCcoreOEM/ Whitelabel/ Licensing Partner · 26 November 2025Parnell acquired Noble Pharma LLC, a U.S.-based FDA- and DEA-accredited pharmaceutical manufacturer located in Menomonie, Wisconsin. The acquisition strengthens Parnell's U.S. manufacturing footprint with capabilities spanning suspensions, liquids, tablets, boluses, powders, gels, pastes, creams, and ointments. This positions Parnell for continued expansion across the U.S. market and enables increased production and innovation.
  • IGNITEcoreStrategic or Co-development PartnerParnell partnered with IGNITE, a veterinary learning company, to develop the Foundations of Anesthesia & Sedation Veterinary Certificate program. The program was created by veterinary professionals in anesthesia, critical care, neurology, and pharmacology and provides 10 RACE-approved CE hours exclusively to clinics purchasing qualifying Parnell manufactured products.

Scale indicators5 records

Recent moves7 records

Expansion highlights7 records

Parnell Living Science competitors and assessment

Company assessment

Direct peers

  • Zoetis: World's largest pure-play animal health company; directly competes across livestock reproductive/respiratory pharmaceuticals and companion-animal anesthesia/sedation, making it Parnell's most direct large-cap peer.
  • Elanco Animal Health: Global animal health pharmaceutical company with overlapping livestock (reproductive, BRD) and companion-animal portfolios; competes head-to-head with Parnell's branded and generic product lines.
  • Merck Animal Health: Animal health division of Merck offering vaccines, pharmaceuticals, and digital tools for livestock and pets; competes with Parnell's livestock reproductive/respiratory portfolio and pet anesthesia/sedation range.
  • Virbac: Independent global animal health company with companion-animal focus including anesthesia/sedation; a close functional peer to Parnell's pet-care anesthesia portfolio (Dexmedetomidine, propofol, isoflurane).
  • Dechra Pharmaceuticals: Specialty veterinary pharma focused on companion-animal endocrinology, anesthesia, and critical care; directly comparable to Parnell's pet-care segment across sedation, euthanasia, and pain products.
  • Phibro Animal Health: Animal health and nutrition company with strong livestock pharmaceutical and medicated feed additive portfolio; comparable to Parnell's livestock product range targeting dairy and beef producers.
  • Vetoquinol: French veterinary pharma with companion-animal and livestock portfolios including reproductive and respiratory products; competes with Parnell in specialty vet pharmaceutical niches across multiple geographies.

Broad incumbents

  • Boehringer Ingelheim Animal Health: Top-3 global animal health franchise offering vaccines, parasiticides, and pharmaceuticals across species; broader portfolio but comparable in livestock reproductive/respiratory therapeutics where Parnell competes.
  • Ceva Santé Animale: Large privately-held animal health company spanning pharmaceuticals, vaccines, and digital monitoring for livestock and pets; competes with Parnell across species but at greater scale and with broader product breadth.

Emerging players

  • Valley Ag Software (DairyComp / PULSE): Dairy herd management software provider with longstanding on-farm installed base; directly competes with mySYNCH for dairy operation data analytics and reproductive program management.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Parnell Living Science social profiles

Digital presence

Parnell Living Science financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Parnell Living Science leadership team

Management profile

Number of profiles

Profiles6 records

Parnell Living Science subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Parnell Living Science funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Parnell Living Science M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Parnell Living Science

What does Parnell Living Science do?

Parnell is a fully integrated veterinary pharmaceutical company that develops, manufactures, and markets FDA- and EMA-approved animal health products for livestock (dairy and beef reproduction and respiratory health) and companion animals (anesthesia, sedation, pain management, euthanasia). The company complements its drug portfolio with the mySYNCH digital herd-management platform, contract manufacturing services, and veterinary continuing-education programs, distributing through major animal-health distributors and herd-health veterinarians in 14 countries.

Is Parnell Living Science a public or private company?

Parnell Living Science is a private company. It is classified as public and is currently operating.

When was Parnell Living Science founded?

Parnell Living Science was founded in 1968. It employs 101 to 250 people.

Where is Parnell Living Science based?

Parnell Living Science is headquartered in Overland Park, United States, in the North America region.

How does Parnell Living Science make money?

Four revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are education and Certificate Programs, contract Manufacturing Services and digital Technology Services (mySYNCH).

Who are Parnell Living Science's main competitors?

Direct peers on record are Zoetis, Elanco Animal Health, Merck Animal Health, Virbac, Dechra Pharmaceuticals, Phibro Animal Health and Vetoquinol. Broad incumbents are Boehringer Ingelheim Animal Health and Ceva Santé Animale. Valley Ag Software (DairyComp / PULSE) is listed as an emerging player.

Does Parnell Living Science have an API?

No public API is recorded for Parnell Living Science.

What industry is Parnell Living Science in?

Parnell Living Science's product category is Veterinary Pharmaceuticals. Its primary akta.pro industry code is AFAEANAK, Veterinary Pharmacy, Vaccine & Biologics Services, with a secondary code of HLAMAEAF, Pain Management, Anesthesia & Critical Care Drugs. Its NAICS code is 541940 and its SIC code is 200.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageParnell Appoints Sharon Holt as Vice President of U.S. Pet CareParnell appointed Sharon Holt as Vice President of U.S. Pet Care, bringing over 20 years of animal health industry experience. She previously held leadership roles at Merial and Boehringer Ingelheim, receiving multiple awards in 2025 and 2026. In her new role, she will lead commercial strategy and growth initiatives for the U.S. Pet Care business.Business Wire BlogParnell Appoints Sharon Holt as Vice President of U.S. Pet CareParnell appointed Sharon Holt as Vice President of U.S. Pet Care, bringing over 20 years of animal health industry experience. She previously held leadership roles at Merial and Boehringer Ingelheim, receiving multiple awards in 2025 and 2026. In her new role, she will lead commercial strategy and growth initiatives for the U.S. Pet Care business.MorningstarParnell Expands PropofolVet Multidose Offering with New 50 mL PresentationParnell announced a new 50 mL presentation of PropofolVet Multidose, a generic propofol injectable emulsion for dogs, complementing its existing 20 mL offering. The product offers a 28-day in-use shelf life with no refrigeration required, aiming to improve inventory management and reduce waste.Business Wire BlogParnell Adds Sevoflurane to Its Growing Veterinary Anesthesia PortfolioParnell announced the launch of Sevoflurane Inhalation Anesthetic for veterinary use in dogs, indicated for induction and maintenance of general anesthesia. The product is nonflammable, nonexplosive, and competitively priced, joining Parnell's existing anesthesia portfolio. The company also promotes its online certificate program to support team competency.ParnellVeterinary Pharmaceuticals for Livestock and PetsParnell Veterinary Pharmaceuticals markets veterinary pharmaceutical products for livestock and pets across 14 countries, utilizing its integrated animal health platform. The company offers specific solutions such as anesthesia agents for pet care and reproductive hormone treatments for livestock, supported by digital technology platforms like mySYNCH.PR NewswireParnell Pharmaceuticals Holdings Ltd Announces Extension of Rights OfferingParnell Pharmaceuticals Holdings Ltd has extended the expiration date of its backstopped rights offering from January 5, 2023 to January 11, 2023, providing additional time for shareholders to participate. The offering aims to raise approximately US$4.0 million in gross proceeds through a private placement of securities under Regulation D of the Securities Act of 1933. Parnell is a fully integrated veterinary pharmaceutical company that manufactures and markets five animal health products across 10 countries.PR NewswireParnell Pharmaceuticals Holdings Ltd Announces Commencement of Rights OfferingParnell Pharmaceuticals Holdings Ltd has commenced a US$4.0 million rights offering, allowing shareholders to purchase shares at US$0.075 each until January 5, 2023. The offering is fully backstopped by existing investors DW Healthcare Partners V, L.P. and DW Healthcare Affiliates V, L.P., who agree to purchase any unsubscribed shares.PR NewswireParnell Pharmaceuticals Holdings Ltd Announces Proposed Rights OfferingParnell Pharmaceuticals Holdings Ltd announced a proposed rights offering to raise US$4.0 million through a backstopped, no-charge distribution of non-transferable subscription rights to qualifying shareholders of record as of December 6, 2022. Existing investors DW Healthcare Partners V, L.P. and DW Healthcare Affiliates V, L.P. have agreed to backstop the offering and purchase all unsubscribed ordinary shares at US$0.075 per share. The securities are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933 and Regulation D, with the subscription period running from December 6, 2022 through January 5, 2023.GlobeNewswireParnell Pharmaceuticals Gives Notice of Annual General Meeting and Explanatory MemorandumParnell Pharmaceuticals Holdings Ltd announced its Annual General Meeting for July 15, 2022, at its Alexandria, NSW headquarters. Shareholders will consider the 2021 financial statements, auditor ratification, and re-election of director Eric Moore. Voting by proxy is available for those unable to attend in person.PR NewswireDWHP Announces Expiration And Final Results Of Its Cash Tender Offer For All Outstanding Ordinary Shares Of Parnell Pharmaceuticals Holdings Ltd.DW Healthcare Partners V, L.P. announced the expiration and final results of its cash tender offer for all outstanding ordinary shares of Parnell Pharmaceuticals Holdings Ltd at $0.40 per share, which expired at 11:59 p.m. New York time on January 28, 2021. A total of 6,241,664 shares representing 29% of aggregate outstanding ordinary shares were validly tendered and accepted for purchase, totaling $2,496,665.60. The transaction is being made pursuant to a Master Transaction Agreement dated November 16, 2020, under which DWHP seeks to acquire a controlling interest of at least 50.01% of Parnell's ordinary shares outstanding.